The BRCA1 c. 5096G > A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

Author(s):
Moghadasi, S.; Meeks, H.D.; Vreeswijk, M.P.G. (0000-0003-4068-9271); Janssen, L.A.M.; Borg, A.; Ehrencrona, H.; Paulsson-Karlsson, Y.; Wappenschmidt, B.; Engel, C.; Gehrig, A.; Arnold, N.; Hansen, T.V.; Thomassen, M.; Jensen, U.B.; Kruse, T.A.; Ejlertsen, B.; Gerdes, A.M.; Pedersen, I.S.; Caputo, S.M.; Couch, F.; Hallberg, E.J.; Ouweland, A.M.W. van den; Collee, M.J.; Teugels, E.; Adank, M.A.; Luijt, R.B. van der; Mensenkamp, A.R.; Oosterwijk, J.C.; Blok, M.J.; Janin, N.; Claes, K.B.M.; Tucker, K.; Viassolo, V.; Toland, A.E.; Eccles, D.E.; Devilee, P. (0000-0002-8023-2009); Asperen, C.J. van (0000-0002-1436-7650); Spurdle, A.B.; Goldgar, D.E.; Garcia, E.G.
Published
2018
Publication type
Article / Letter to editor
Date issued
2018-01-31
Language
English
Is part of
Journal of Medical Genetics (2018), Vol. 55, no. 1, p. 15-20
hdl
1887/116021
doi
10.1136/jmedgenet-2017-104560